What are the presentation, diagnostic workup, and management strategies for ulcerative colitis in pediatric patients?

Pediatric Ulcerative Colitis: Overview, Presentation, Diagnosis, and Management

Overview

Pediatric ulcerative colitis (UC) is a chronic inflammatory disorder of the colon that affects approximately 20% of all UC patients, with distinct management considerations compared to adult disease, particularly regarding growth, nutrition, and psychosocial development. The disease shares many features with adult-onset UC but requires adapted therapeutic approaches due to unique pediatric considerations 1, 2.

The incidence of pediatric inflammatory bowel disease is increasing globally 3, 4. Unlike adult disease, pediatric UC presents additional complexities including:

• Growth impairment and delayed puberty
• Nutritional deficiencies requiring specific attention
• Psychosocial challenges affecting school performance and social development
• Higher rates of extensive colitis at presentation
• Approximately 20% require colectomy during childhood years 2

Clinical Presentation

Children with UC typically present with bloody diarrhea, abdominal pain, urgency, tenesmus, and weight loss, often with more extensive disease than adults at diagnosis 5, 6.

Key Clinical Features:

• Gastrointestinal symptoms:

  • Bloody diarrhea (hallmark symptom)
  • Increased stool frequency with urgency
  • Abdominal cramping and pain
  • Tenesmus
  • Fecal incontinence (may occur)

• Systemic manifestations:

  • Weight loss and failure to thrive
  • Growth retardation
  • Delayed puberty
  • Fever (in severe cases)
  • Fatigue and malaise

• Extraintestinal manifestations:

  • Arthritis/arthralgia
  • Erythema nodosum, pyoderma gangrenosum
  • Primary sclerosing cholangitis
  • Uveitis/episcleritis
  • Oral aphthous ulcers

Severity Assessment

Use the Pediatric Ulcerative Colitis Activity Index (PUCAI) for standardized disease activity assessment 1, 2. The PUCAI is a validated, non-invasive tool that guides therapeutic decisions:

• Remission: PUCAI <10
• Mild disease: PUCAI 10-34
• Moderate disease: PUCAI 35-64
• Severe disease: PUCAI ≥65

For severe disease requiring hospitalization, the Truelove and Witts criteria remain valid: bloody stool frequency ≥6/day PLUS one of: tachycardia (>90/min), fever (>37.8°C), anemia (Hb <10.5 g/dL), or ESR >30 mm/h (or CRP >30 mg/L) 7.

Diagnostic Workup

Diagnosis requires colonoscopy with biopsies demonstrating chronic colitis, after excluding infectious causes 1, 6.

Initial Evaluation:

1. Laboratory investigations:

   • Complete blood count (assess anemia, thrombocytosis)
   • ESR and CRP (inflammatory markers)
   • Albumin (nutritional status and disease severity)
   • Liver function tests (screen for PSC)
   • Fecal calprotectin and lactoferrin (elevated in active disease) 5
   • Fecal occult blood

2. Stool studies (mandatory to exclude infection):

   • Bacterial culture (Salmonella, Shigella, Campylobacter, E. coli O157:H7)
   • Clostridium difficile toxin
   • Ova and parasites
   • Consider CMV testing in severe/refractory cases

3. Imaging:

   • Abdominal X-ray (assess for toxic megacolon, proximal constipation)
   • CT or MRI enterography if Crohn's disease cannot be excluded
   • Ultrasound may show bowel wall thickening 5

4. Endoscopic evaluation:

   • Complete colonoscopy with ileoscopy and multiple biopsies is essential 1, 2
   • Perform upper endoscopy to exclude Crohn's disease
   • Document disease extent (proctitis, left-sided, extensive/pancolitis)

   Endoscopic features:

   • Loss of vascular pattern
   • Erythema and granularity
   • Friability with contact bleeding
   • Erosions and ulcerations
   • Continuous inflammation starting from rectum
   • Pseudopolyps in chronic disease

5. Histopathology:

   • Chronic inflammation with basal plasmacytosis
   • Crypt architectural distortion
   • Crypt abscesses
   • Goblet cell depletion
   • Absence of granulomas (distinguishes from Crohn's)

Common Diagnostic Pitfalls:

• Failing to exclude infectious colitis before starting immunosuppression
• Not performing upper endoscopy (may miss Crohn's disease)
• Inadequate biopsy sampling
• Misdiagnosing IBD-unclassified as definite UC

Management Strategy

Management is based on disease severity (PUCAI score), extent, and response to therapy, with the goal of achieving steroid-free clinical and endoscopic remission while optimizing growth 1, 2, 6.

Mild Disease (PUCAI 10-34)

For mild proctitis, start with mesalamine 1g suppository once daily 7, 2.

• Suppositories deliver drug more effectively to rectum than foam or enemas
• More effective than topical steroids
• Combining topical with oral mesalamine (≥2.4 g/day) is more effective than either alone

For mild left-sided or extensive colitis, use combination therapy: topical mesalamine (≥1g/day enema) PLUS oral mesalamine (≥2.4 g/day) 7, 2.

• Once-daily dosing is as effective as divided doses and improves adherence
• Higher doses (4.8 g/day) may benefit moderate disease
• Continue for 8 weeks before declaring treatment failure

Moderate Disease (PUCAI 35-64)

Start oral prednisone (1 mg/kg/day, maximum 40-60 mg) combined with oral and topical mesalamine 2, 6.

If inadequate response after 2 weeks or persistent rectal bleeding beyond 10-14 days:

• Escalate to higher-dose mesalamine (4.8 g/day) OR
• Consider early introduction of thiopurine (azathioprine 2-2.5 mg/kg/day or mercaptopurine 1-1.5 mg/kg/day) OR
• Consider anti-TNF therapy (infliximab or adalimumab)

For steroid-dependent disease (inability to taper below equivalent of prednisone 10 mg/day within 3 months), use thiopurines, anti-TNF therapy (preferably infliximab combined with thiopurine), or vedolizumab 7, 2.

Severe Disease (PUCAI ≥65)

Severe UC requires immediate hospital admission for intensive intravenous therapy 7, 6.

Initial management:

1. IV methylprednisolone 1-2 mg/kg/day (maximum 60 mg) or hydrocortisone 100 mg every 6 hours 6
2. Assess response at Day 3 using clinical parameters and CRP
3. If no improvement by Day 3-5, proceed to medical rescue therapy OR colectomy

Medical rescue therapy options for steroid-refractory severe UC:

• Infliximab 5 mg/kg at weeks 0,2,6 (preferred in most centers) 7, 6

  • Consider accelerated dosing in severe cases
  • Combination with thiopurine improves outcomes (UC-SUCCESS trial showed 39.7% steroid-free remission with combination vs 22.1% with infliximab alone) 7

• Cyclosporine 2 mg/kg/day IV (target trough 200-400 ng/mL) or tacrolimus oral (target trough 10-15 ng/mL) 7, 6

  • Response rates 68% for high-trough tacrolimus vs 10% placebo
  • Bridge to thiopurine or anti-TNF maintenance
  • Higher infection risk; requires close monitoring

One-year remission rates after medical rescue therapy are under 50%; colectomy should be discussed early 6.

Maintenance Therapy

After achieving remission, maintenance therapy is essential:

• Mild disease: Mesalamine (oral ± topical) indefinitely 2
• Moderate disease requiring steroids: Thiopurine or anti-TNF 2
• Severe disease/rescue therapy: Anti-TNF (infliximab or adalimumab) with or without thiopurine 2, 6

Vedolizumab is an alternative for patients who fail or are intolerant to anti-TNF therapy 7, 2.

Therapeutic Drug Monitoring

Use therapeutic drug monitoring for anti-TNF therapy to optimize outcomes 2:

• Target infliximab trough: 5-10 μg/mL during maintenance
• Target adalimumab trough: 8-12 μg/mL
• Adjust dosing based on drug levels and antibody formation

Treatment Targets

Aim for steroid-free clinical remission (PUCAI <10) AND endoscopic healing (Mayo endoscopic subscore 0-1) 2.

• Monitor fecal calprotectin (<250 μg/g suggests mucosal healing)
• Repeat colonoscopy if symptoms persist despite normal calprotectin
• Histologic remission is emerging as an additional target

Surgical Management

Indications for colectomy:

• Failure of medical rescue therapy in acute severe colitis
• Medically refractory chronic disease
• Dysplasia or colorectal cancer
• Growth failure despite optimal medical therapy
• Intolerable medication side effects

Ileal pouch-anal anastomosis (IPAA) is the procedure of choice 8.

• Typical stool frequency post-IPAA: 4-8 bowel movements/day
• Pouchitis occurs in 30-50% of patients
• Outcome generally good for pediatric patients

Special Considerations in Pediatrics

Growth and nutrition:

• Monitor height, weight, and pubertal development at every visit
• Correct nutritional deficiencies (iron, vitamin D, B12, zinc)
• Consider exclusive enteral nutrition as adjunctive therapy 2, 4
• Minimize steroid exposure to prevent growth suppression

Psychosocial support:

• Screen for anxiety and depression
• Provide age-appropriate disease education
• Support school attendance and social activities
• Consider mind-body interventions 4

Transition planning:

• Begin structured transition program by age 12-14
• Transfer to adult care typically at age 18-21
• Ensure continuity of therapeutic relationships 4

Monitoring During Therapy

Regular monitoring schedule:

• Clinical assessment with PUCAI every 3 months
• Fecal calprotectin every 3-6 months
• CBC, liver function, inflammatory markers every 3-6 months
• Thiopurine metabolites if on azathioprine/mercaptopurine
• Anti-TNF drug levels and antibodies as needed
• Annual colonoscopy if not in remission; every 1-2 years once stable

Emerging Therapies

Newer agents under investigation for pediatric use include:

• JAK inhibitors (tofacitinib, upadacitinib) - showing promise in adults 7, 4
• Ustekinumab (IL-12/23 inhibitor) 4
• Fecal microbiota transplantation (investigational) 4
• Stem cell therapy (early research phase) 4

Key Pitfalls to Avoid

1. Delaying escalation in steroid-dependent patients - leads to growth impairment and steroid toxicity
2. Undertreating with inadequate mesalamine doses - use ≥2.4 g/day, preferably 4.8 g/day for moderate disease
3. Not combining topical and oral therapy - combination is significantly more effective
4. Failing to monitor for CMV or C. difficile in refractory cases - can mimic treatment failure
5. Inadequate therapeutic drug monitoring - leads to suboptimal anti-TNF dosing
6. Not addressing growth and nutrition proactively - irreversible if delayed
7. Prolonged steroid use without bridge to steroid-sparing agent - causes significant morbidity

The management algorithm should be PUCAI-driven, with early escalation to biologics for moderate-severe disease, combination therapy when appropriate, and vigilant monitoring of growth, nutrition, and therapeutic targets to optimize long-term outcomes 1, 2.